Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 4/20 | 0.55 |
| ▸ | FLT1 | P17948 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | SCD | O00767 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22854454 | 0.88 | ALDH1A1 (0.68) | ALDH1A1ADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL6014596 | 0.87 | ADRA1D (0.61) | ALDH1A1ADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL1715953 | 0.85 | KDM4C (0.61) | ALDH1A1KDM4EGLAGAAKMT2A | |
| SCHEMBL1715133 | 0.85 | KDR (0.55) | ALDH1A1ADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL1714827 | 0.84 | ALDH1A1 (0.53) | ALDH1A1ADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL5718299 | 0.83 | CDC7 (0.64) | ALDH1A1KDM4EPOLBADRA2CKDR | |
| SCHEMBL1715089 | 0.83 | KDM4C (0.70) | ALDH1A1KDM4EPOLBADRA2CKDR | |
| SCHEMBL1523353 | 0.83 | KDM4C (0.62) | ALDH1A1ADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL1715126 | 0.82 | MAPT (0.60) | ALDH1A1ADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL3151267 | 0.82 | KDR (0.64) | ALDH1A1KDM4EPOLBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| US-7479491-B2 | Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors | NOVARTIS AG (CH) | 2009-01-20 | — | — | US | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-6818661-B2 | FOR THERAPY OF PSORIASIS, ARTHRITIS, SUCH AS RHEUMATOID ARTHRITIS, HAEMANGIOMA, ANGIOFIBROMA, EYE DISEASES SUCH AS DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, KIDNEY DISEASES SUCH AS GLOMERULONEPHRITIS, DIABETIC NEPHROPATHY | NOVARTIS AG (CH) | 2004-11-16 | — | — | US | disclosed |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2004-10-07 | — | — | US | disclosed |
| US-20030176469-A1 | Anthranylalkyl and cycloalkyl amides and use thereof as vegf receptor inhibitors | NOVARTIS AG (CH) | 2003-09-18 | — | — | US | disclosed |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2003-04-03 | — | — | US | disclosed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
| EP-1129075-A1 | N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2001-09-05 | — | — | EP | disclosed |
| EP-1129074-A2 | ANTRHRANILIC ACID AMIDES AND THE USE THEREOF AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027820-A1 | N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000027819-A2 | ANTRHRANILIC ACID AMIDES AND THE USE THEREOF AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | ALDH1A1 2918/4885ADRA1D 931/4885ADRA1A 1488/4885 |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TP53, MCL1, VHL | ALDH1A1 535/4885ADRA1D 4732/4885ADRA1A 4506/4885 |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | ABCC3, HCCS, ABCC2 | ALDH1A1 611/4885ADRA1D 703/4885ADRA1A 940/4885 |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | ALDH1A1 2909/4885ADRA1D 914/4885ADRA1A 1300/4885 |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | ALDH1A1 3031/4885ADRA1D 1004/4885ADRA1A 1572/4885 |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | TP53, MCL1, VHL | ALDH1A1 535/4885ADRA1D 4732/4885ADRA1A 4506/4885 |
| US-20030176469-A1 | Anthranylalkyl and cycloalkyl amides and use thereof as vegf receptor inhibitors | KDR, FLT1, VEGFA | ALDH1A1 588/4885ADRA1D 429/4885ADRA1A 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.